Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Aldel Financial Inc Cl A
Arcimoto, Inc. - Common Stock
Bank of Nova Scotia
Barings Global Short Duration High Yield Fund Common Shares of Beneficial
Chicken Soup for the Soul Entertainment, Inc. - Class A Common Stock
Eco Innovation Grp Inc
Howard Hughes Corporation (The) Common Stock
InnovAge Holding Corp. - Common Stock
Ironnet Inc
Niu Technologies - American Depositary Shares
Pretium Resources, Inc. Ordinary Shares (Canada)
Select Interior Concepts, Inc. - Class A Common Stock
Sigma Labs, Inc. - Common Stock
Silo Wellness Inc
Silo Wellness Inc
Volcon, Inc. - Common stock
Volta Inc
WiMi Hologram Cloud Inc. - Class B Ordinary Shares
Edit Watchlist
Top Indices
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
My Portfolio
Articles published by Allogene Therapeutics, Inc.
< Previous
1
2
3
4
Next >
Allogene Therapeutics Reports First Clinical Data from Phase 1 RESOLUTION Study of ALLO-329 in Autoimmune Disease
November 09, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics Reports Third Quarter 2026 Financial Results and Business Update
November 05, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Highlights Clinical Progress and Next-Generation Innovation Across Its Off-the-Shelf CAR T Platform at SITC Annual Meeting
November 03, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics Announces November Investor Events Highlighting Q3 Results and Initial ALLO-329 Autoimmune Clinical Data
October 29, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
October 26, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker
September 02, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics Announces Participation in September Investor Conference
August 31, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update
August 12, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update
August 04, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma
July 29, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors
July 15, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics Announces Planned CEO Succession
May 28, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
May 26, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update
May 13, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
May 06, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia
April 21, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026
April 20, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock
April 16, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases
April 15, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics Announces Pricing of Public Offering of Common Stock
April 14, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock
April 13, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL
April 13, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026
April 10, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
March 12, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update
March 02, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
February 05, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T
January 08, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis
December 15, 2025
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
CLLS
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
November 10, 2025
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update
November 06, 2025
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.